(ii) 10 to 14: Potential low-level resistance. The virus is likely to be fully susceptible yet it contains mutations that may be indicative of previous exposure to the ARV class of the drug; (iii) 15 to 29: Low-level resistance. Virus isolates of this type have reduced invitro drug-susceptibility and/or patients with viruses of this genotype may have a suboptimal virologic response to treatment compared with the treatment of a wildtype virus; (iv) 30 to 59: The genotype suggests a degree of drug resistance greater than lowlevel resistance but lower than high-level resistance; (v) ≥ 60: the genotype is similar to that of isolates with the highest levels of in vitro drug resistance and/or patients infected with isolates having similar genotypes generally have little or no virologic response to treatment with the drug. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Table 4: Prevalence of predicted intermediate or high level resistance to DHHS recommended starting drugs according to the Stanford HIVDB 5-point resistance scale |
